Anticipate generic drug launch
Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Manage your formulary budget
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Dispersible macromolecule compositions and methods for their preparation and use|
|Abstract:||A process for preparing ultrafine powders of biological macromolecules comprises atomizing liquid solutions of the macromolecules, drying the droplets formed in the atomization step, and collecting the particles which result from drying. By properly controlling each of the atomization, drying, and collection steps, ultrafine dry powder compositions having characteristics particularly suitable for pulmonary delivery for therapeutic and other purposes may be prepared.|
|Inventor(s):||Platz; Robert (Half Moon Bay, CA), Brewer; Thomas (Booneville, CA), Boardman; Terrence (Los Altos, CA)|
|Assignee:||Nektar Therapeutics (San Carlos, CA)|
|Filing Date:||Mar 31, 2003|
|Claims:||1. A method for preparing dispersible dry powders of biological macromolecules, said method comprising: providing an evaporable liquid medium containing a macromolecule selected from the group consisting of proteins, polypetides, oligopeptides, nucleic acids, and polysaccharides, wherein the concentration of total solids in the liquid medium is less than 10% by weight; atomizing the liquid medium consisiting of said marcomolecule to form droplets by flowing the liquid medium and an atomization gas stream at a gas:liquid mass flow ratio above 5 under conditions selected to form droplets having an average size of between 5 .mu.m and 11 .mu.m; and drying the droplets in a single drying step, in a heated gas stream, wherein the heated gas stream has an outlet temperature of at least 70.degree. C., to produce particles having a rugosity of at least 2.0 as measured by air permeametry, wherein 90% of the mass of the powder comprises particles having a diameter in the range of between about 0.1 microns and about 7 microns, and wherein the particles have a final moisture content of below 5% by weight. |
2. A method of claim 1 further comprising collecting said particles.
3. A method as in claim 1 wherein 90% of the mass of the powder comprises particles having a diameter within the range of 0.4 microns 5 microns.
4. A method as in claim 1 further comprising packaging at least some of the particles in a container, wherein the particles have not been size classified prior to packaging.
5. A method as in claim 4 wherein the particles are packaged in a unit dosage container.
6. A method as in claim 1 wherein the macromolecule is selected from the group consisting of calcitonin, reythropoietin, factor IX, granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, growth hormone, insulin, interferon alpha, interferon beta, interferon gamma, interleukin-2, leutenizing hormone releasing hormone (LHRH), somatostatin, vasopressin analog, follicle stimulating hormone (FSH), amylin, ciliaryneurotrophic factor, growth hormone releasing factor (GRE), insulin-like growth factor, insulinotropin, interleukin-1 receptor antagonist, interleukin-3, interleukin-4, interleukin-6, macrophage colony stimulating factor(M-CSF), nerve growth factor, parathyroid hormone, thymosin alpha 1, factor IIb/IIIa inhibitor, alpha-1 antitrypsin, anti-RSV antibody, deoxyribonuclease (DNase), bactericidal/permeability increasing protein (BPI), anti-CMV antibody, interleukin-1 receptor, and interleukin-1 receptor antagonist.
7. A method as in claim 1 wherein the particles comprise a rugosity measured by air permeability in the range from 3 to 6.
8. A method as in claim 1 wherein the liquid medium comprises an excipient.
9. A method as in claim 1 wherein the liquid medium comprises a solution or suspension.
10. A method as in claim 9 wherein the liquid medium comprises an aqueous solution.
11. A method as in claim 1 wherein the liquid medium comprises ethanol.
12. A composition prepared by the method of claim 1.
13. A composition as in claim 12 wherein the macromolecule is insulin.
14. A composition as in claim 12 in a unit dosage form containing 0.5 mg 15 mg of the composition.
15. A composition as in claim 12 comprising an excipient selected from the group consisting of carbohydrates, amino acids, buffers and salts.
16. A composition as in claim 14 wherein the excipient is selected from the group consisting of monosaccharides, disaccharides, polysaccharides, and hydrophobic amino acids.
17. A composition as in claim 15 wherein the excipient is selected from the group consisting of manitol, trehalose, sodium chloride, sodium citrate, leucine, lactose, raffinose, alanine, and glycine.
18. A method as in claim 1 wherein 95% of the mass of the powder comprises particles having a diameter within the range of 0.4 microns 5 microns.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.